Dr. Marc Rubin was among other things responsible for Spheramine.
For me it seems that Spheramine is on a good way. I am wondering when Bayer will release results of the current study.

Here is the PR
Titan Adds Dr. Marc Rubin to Executive Management Team as President and Chief Executive Officer
Wednesday September 26, 9:20 am ET


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc. (AMEX: TTP - News) today announced that Dr. Marc Rubin, M.D. will join Titan as President and Chief Executive Officer starting October 1, 2007. Dr. Rubin will also be a member of the Board of Directors.
ADVERTISEMENT


Dr. Rubin was formerly the Head of Global Research and Development for Bayer Schering Pharma, and a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma.

Dr. Louis R. Bucalo, Titan's founder and current Chairman, President and Chief Executive Officer, who led the recruitment of Dr. Rubin, will continue as Chairman of the Company.

"We are very pleased to have Marc join Titan as President and CEO," stated Dr. Bucalo. "Marc's 18 years of industry experience and record of success in pharmaceutical development make him an exceptional industry leader, and an outstanding person to lead Titan forward to future achievements. Titan's several products in development, including iloperidone which completed Phase III testing for schizophrenia, Probuphine® in Phase III testing for opiate addiction, and Spheramine® in Phase IIb testing for advanced Parkinson's disease, as well as our other products in earlier stage development, provide a strong foundation for future growth. I and our Board of Directors have great confidence that Marc, together with our management team, will continue to drive our company forward to a successful future."

"I am delighted to join Titan and help lead the company forward," stated Dr. Rubin. "Titan is poised to enter an exciting phase and has built an excellent platform for future growth. With innovative programs spanning early and late stage development, we have a tremendous opportunity to provide significant advances in innovative new therapeutics."

Prior to his position at Bayer Schering Pharma, Dr. Rubin was a Member of the Executive Board and President of Development for Schering AG, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. His position included responsibility for 3 Global Business Units.

Before joining Schering AG, Dr. Rubin held several positions of increasing responsibility at GlaxoSmithKline, with development as well as commercial responsibility. There he had oversight of the development, approval and commercial strategy for numerous pioneering programs.

Dr. Rubin received his MD from Cornell University Medical College in 1980, and completed his Internship and Residency at The Johns Hopkins Hospital, and subspecialty training at the National Institutes of Health.